3Bahlis N J, MeCafferty - G J, Jordan - Mc Mur- ry I, et al. Feasibility and eorrelate 8 of arsenic trioxde combined with ascerbic acid Mediated depletion of intmce Hular ghtathione for the treatment of relapsed/refractory multiple my- elom[ J ]. Clin Cancer Res, 2002,8 : 3658 - 3668.
3Rousselot P, Larghero J, Labaume S, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol, 2004; 72: 166-171
4Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol, 2004; 125:470-476
5Kajiguchi T, Yamamoto K, Iida S, et al. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxideinduced cell apoptosis in multiple myeloma cell lines. Cancer Sci, 2006; 97:540-545
6Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukemia cell lines in vitro: activation of caspases and downregulation of Bcl2 protein. Br J Haematol, 1998; 102:1055-1060
7Jiang F, Bao J, Li P, et al. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem, 2004; 279:53213-53221
